Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Reprixys Pharmaceutical Corporation
- Target Recruit Count
- 198
- Registration Number
- NCT01895361
© Copyright 2025. All Rights Reserved by MedPath